BOND-003 Study
Clinicaltrials.gov ID:
NCT04452591
CG Oncology Study ID:
Cretostimogene grenadenorepvec (CG0070)
Condition:
Non-Muscle Invasive Bladder Cancer
Contact:
Recruitment@cgoncology.com
A Study of Intravesical CG0070 for Treatment of Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
The BOND-003
study is testing an investigational drug called cretostimogene grenadenorepvec (CG0070) for adults with non-muscle invasive bladder cancer (NMIBC) who have already tried BCG treatment. Cretostimogene grenadenorepvec (CG0070) is a type of immunotherapy, which is different from chemotherapy. Immunotherapy is a type of cancer treatment that helps your immune system fight cancer.
In this study,
Cretostimogene grenadenorepvec (CG0070) will be given intravesically, meaning it is put directly into the bladder using a catheter (a thin tube put into your bladder). Throughout the study doctors will monitor your health and how your cancer is responding to the treatment.
Patient Eligibility
Study Site Locations
